AGM/EGM21 Aug 2026, 07:30 pm
Astonea Labs Expands MOA Objects for Pharma & Healthcare Business
AI Summary
Astonea Labs Ltd announced that its members, at the 9th Annual General Meeting held on August 21, 2026, approved a special resolution to alter the Object Clause of the Memorandum of Association (MOA). This alteration aims to broaden the company's business scope to include manufacturing, processing, marketing, distribution, and sale of pharmaceutical, nutraceutical, healthcare, and ayurvedic products. The company will also engage in various commercial channels like retail, wholesale, institutional sales, franchising, and e-commerce. This strategic move aligns the company's objectives with its existing and proposed business activities in the health and wellness sector.
Key Highlights
- MOA object clause altered via special resolution at AGM.
- Expands business scope to pharma, nutraceutical, healthcare, ayurvedic products.
- Includes new distribution channels like e-commerce and franchising.
- Aims to align company objectives with current and future business plans.
Price Impact
More from ASTONEALAB